Hematologic Malignancies Market - Forecast(2024 - 2030)

Report Code: HCR 62568 Report Format: PDF + Excel

Hematologic Malignancies Market Overview

The Hematologic Malignancies Market size was estimated at $42.4 billion in 2020, projected to grow at a CAGR of 10.2% during the forecast period 2021-2026. Hematopoietic stem and progenitor cells in the bone marrow give rise to a variety of mature blood cells, including red blood cells for carrying oxygen, white blood cells for immune defense, and platelets for wound clotting. Hematologic malignancies are cancers that start in these cells and are classified by the type of blood cell that is affected. They are typically divided into three groups based on whether the cancer is first discovered in the blood (leukemias), lymph nodes (lymphomas - Hodgkin and non-Hodgkin), or bone (osteosarcomas) (myelomas). 

In economically developed regions of the world, haematological malignancies are the fifth most common cancer type. Furthermore, each year, over 300,000 people are diagnosed with leukaemia and 400,000 with lymphoma around the world. The rising prevalence of these diseases is the primary driver of the market's expansion. Increased government support for research and development, and increased awareness among healthcare professionals and patients about the likelihood of early cancer detection are other factors expected to drive market growth during the forecast period 2021-2026. However, the high costs associated with clinical services and stringent regulations along with certain side-effects associate with the treatments is set to restrain to the market's growth during the forecast period 2021-2026.

Report Coverage

The report: “Hematologic Malignancies Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Hematologic Malignancies Market.
By Type: Leukemia, Lymphoma and Multiple myeloma.
By Treatment: Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation and Others.
By End User: Hospitals, Diagnostic Centers, Research Centers, and Others.
By Geography: North America (U.S, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Others), Asia-Pacific (China, Japan India, South Korea, Australia and Others), South America(Brazil, Argentina and others) and Rest of the World (Middle East and Africa).

Key Takeaways

  • Geographically, The North America region held 37.4% of the total market share in 2020 owing to the supportive government programs and policy’s, and established healthcare infrastructure for Hematologic Malignancies.
  • The increasing prevalence and incidence of these diseases are the major factor driving the Hematologic Malignancies Market during forecast period 2021-2026.
  • Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Hematologic Malignancies Market.

Hematologic Malignancies Market - By Geography, 2020.

Hematologic Malignancies Market

For more details on this report - Request for Sample

Hematologic Malignancies Market Segment Analysis- By Type

On the basis of type, the market is divided into three segments leukemia, lymphoma, and multiple myeloma. Acute lymphocytic, chronic lymphocytic, acute myeloid, and chronic myeloid leukemia are the four types of leukemia. Acute lymphocytic leukemia (ALL) is the most common form of leukemia, accounting for 56% of cases in adolescents and 80% in children between 2016 and 2017. For instance According to a study conducted by The Leukemia & Lymphoma Society, leukemia was the sixth most common cause of cancer deaths in both men and women in the US. 

Moreover, about 60,530 cases are expected to be diagnosed with leukemia, in 2020. While, 23,100 people including 13,420 males and 9,680 females are expected to die from leukemia in 2020. However Due to a strong product pipeline and planned commercialization, acute myeloid is expected to grow at a faster CAGR of 12.8% during the forecast period 2021-2026.

Hematologic Malignancies Market Segment Analysis - By Treatment

Based on treatment, the global Hematologic Malignancies Market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation and Others treatments. Chemotherapy, which is the first line of treatment, was the most dominating segment in 2020. Chemotherapy is the standard treatment for certain cases of blood cancer, although depending on the type of cancer, a specific drug or combination of drugs is used. However, Immunotherapy is expected to develop at the highest rate of 11.4% during the forecast period 2021-2026 owing to the lower adverse effects and the higher efficiency

Hematologic Malignancies Market Segment Analysis - By Geography

Based on geography, North America dominated the Hematologic Malignancies Market with a region share of 37.4% in 2020 followed by Europe and APAC. The supportive government programs and policy’s, and established healthcare infrastructure for Hematologic Malignancies are the major factor propelling the growth in this region. Furthermore, the existence of a large number of pharmaceutical companies that invest heavily in Hematologic Malignancies research, as well as the easy availability of technologically advanced drugs, is expected to propel the market in this area forward.

However, Asia Pacific region is predicted to see the demand maturing in Hematologic Malignancies Market owing to the increasing healthcare expenditure and infrastructure that supports early diagnosis. Furthermore, policymakers in developing countries are taking steps to raise awareness about Hematologic Malignancies, as well as their diagnosis and treatment options which is further predicted to drive the market during the forecast period 2021-2026.

Hematologic Malignancies Market Drivers

Increasing Incidence of Disease

The rising occurrence of blood cancer, as well as an increasing awareness of the disease's probability at an early stage, are two major factors driving the market. Nearly one person in the United States is diagnosed with blood cancer every three minutes, according to the Leukemia & Lymphoma Society (LLS). Moreover according to the international agency for research on cancer an estimated 10.1 lakh new cases, while 7 lakh death with Hematologic Malignancies were registered in 2020.

Furthermore, the easy availability of several medicines to treat Hematologic Malignancies along with the increasing investments by key market player and government organizations around the world, is set to propel the market forward during the forecast period 2021-2026.

Hematologic Malignancies Market Challenges

High Cost of the Product

Despite the increase in Hematologic Malignancies cases and supportive government programs and policy’s, some factors are preventing product acceptance. The high costs associated with clinical trials along with certain side-effects associate with the therapy is currently limiting the adoption of the products. Moreover the rising stringency in the government regulation also poses a major threat thereby, acting as major impediment for market's growth.

Hematologic Malignancies Market Landscape:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Hematologic Malignancies Market. Key companies of this market are laxoSmithKline Pharmaceutical Ltd., AbbVie, Inc, Takeda Pharmaceutical Company Limited, Celgene Corporation, Pfizer, Inc., Abbott Laboratories, F. Hoffmann-LA Roche ltd., AstraZeneca, Pharmacyclics, Janssen Pharmaceutical Companies, and others.   

Developments:

  • In August 2020, The FDA has approved GlaxoSmithKline Pharmaceutical Ltd's BLENREP (belantamab mafodotin-blmf), which is used to treat patients with multiple myeloma.

Relevant reports

Report Code: HCR 0194

Report Code: HCR 12157

 For more Lifesciences and Healthcare related reports, please click here
1. Hematologic Malignancies Market Overview
    1.1 Definitions and Scope
2. Hematologic Malignancies Market Executive Summary
    2.1 Market Revenue, Market Size and Key Trends
    2.2 Key trends By Type
    2.3 Key trends By Treatment
    2.4 Key trends By End-Users
    2.5 Key trends By Geography
3.  Hematologic Malignancies Market Landscape
    3.1 Product Benchmarking- Key Companies
    3.2 Financial Analysis- Key Companies
    3.3 Patent Analysis
    3.4 Pricing Analysis- Average Pricing
4. Hematologic Malignancies Market- Startup companies Scenario Premium Premium
    4.1 Key startup company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Application Analysis
        4.1.4 Venture Capital and Funding Scenario
5. Hematologic Malignancies Market- Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of successful ventures
6. Hematologic Malignancies Market Forces
    6.1 Market Drivers
    6.2 Market Constraints and Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining Power of Suppliers
        6.3.2 Bargaining Powers of Customers
        6.3.3 Threat of New Entrants
        6.3.4 Rivalry Among Existing Players
        6.3.5 Threat of Substitutes
7. Hematologic Malignancies Market Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Hematologic Malignancies Market– By Type
    8.1 Leukemia
        8.1.1 Acute Lymphocytic Leukemia (ALL)
        8.1.2 Chronic Lymphocytic Leukemia (CLL)
        8.1.3 Acute Myeloid Leukemia (AML)
        8.1.4 Chronic Myeloid Leukemia (CML)
    8.2  Lymphoma
        8.2.1 Non-Hodgkin Lymphoma
        8.2.2 Hodgkin Lymphoma
    8.3 Multiple Myeloma
9. Hematologic Malignancies Market– By Treatment
    9.1 Chemotherapy
    9.2 Radiotherapy
    9.3 Immunotherapy
    9.4 Stem Cell Transplantation
    9.5 Others
10. Hematologic Malignancies Market– By End User
    10.1 Hospitals
    10.2 Diagnostics Centers
    10.3 Research Centers
    10.4 Others
11. Hematologic Malignancies Market- By Geography
    11.1 North America
        11.1.1 U.S
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K
        11.2.2 Germany
        11.2.3 France
        11.2.4 Spain
        11.2.5 Italy
        11.2.6 Russia
        11.2.7 Rest of Europe
    11.3 Asia Pacific
        11.3.1 India
        11.3.2 China
        11.3.3 Japan
        11.3.4 Australia
        11.3.5 South Korea
        11.3.6 Rest of Asia pacific
    11.4 South America
        11.4.1 Brazil
        11.4.2 Argentina
        11.4.3 Rest of South America
    11.5 Rest of the World
        11.5.1 Middle East
        11.5.2 Africa
12. Hematologic Malignancies Market Entropy
13. Hematologic Malignancies Market- Industry / Segment Competition landscape Premium Premium
    13.1 Market Share Analysis
        13.1.1 Market Share by Country- Key companies
        13.1.2 Market Share by Region- Key companies
        13.1.3 Market Share at Global Level- Key companies
        13.1.4 Best Practices for Companies
14. Hematologic Malignancies Market- Key Company List by Country Premium Premium
15. Hematologic Malignancies Market Company Analysis (Company Revenue, Products, M&A, Developments)
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10
    "*Financials for private companies would be provided on a best efforts basis”.

LIST OF TABLES

1.Global Competitive Landscape Market 2023-2030 ($M)
1.1 Market Participation Categorization Market 2023-2030 ($M) - Global Industry Research
1.1.1 Pfizer Inc Market 2023-2030 ($M)
1.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
1.1.3 Sanofi Market 2023-2030 ($M)
1.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
1.1.5 AbbVie Inc Market 2023-2030 ($M)
1.1.6 Novartis AG Market 2023-2030 ($M)
1.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
1.1.8 Celgene Corporation Market 2023-2030 ($M)
1.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
1.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)
2.Global Competitive Landscape Market 2023-2030 (Volume/Units)
2.1 Market Participation Categorization Market 2023-2030 (Volume/Units) - Global Industry Research
2.1.1 Pfizer Inc Market 2023-2030 (Volume/Units)
2.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 (Volume/Units)
2.1.3 Sanofi Market 2023-2030 (Volume/Units)
2.1.4 Bristol-Myers Squibb Company Market 2023-2030 (Volume/Units)
2.1.5 AbbVie Inc Market 2023-2030 (Volume/Units)
2.1.6 Novartis AG Market 2023-2030 (Volume/Units)
2.1.7 GlaxoSmithKline PLC Market 2023-2030 (Volume/Units)
2.1.8 Celgene Corporation Market 2023-2030 (Volume/Units)
2.1.9 Johnson Johnson Services, Inc Market 2023-2030 (Volume/Units)
2.1.10 Takeda Pharmaceutical Company Market 2023-2030 (Volume/Units)
3.North America Competitive Landscape Market 2023-2030 ($M)
3.1 Market Participation Categorization Market 2023-2030 ($M) - Regional Industry Research
3.1.1 Pfizer Inc Market 2023-2030 ($M)
3.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
3.1.3 Sanofi Market 2023-2030 ($M)
3.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
3.1.5 AbbVie Inc Market 2023-2030 ($M)
3.1.6 Novartis AG Market 2023-2030 ($M)
3.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
3.1.8 Celgene Corporation Market 2023-2030 ($M)
3.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
3.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)
4.South America Competitive Landscape Market 2023-2030 ($M)
4.1 Market Participation Categorization Market 2023-2030 ($M) - Regional Industry Research
4.1.1 Pfizer Inc Market 2023-2030 ($M)
4.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
4.1.3 Sanofi Market 2023-2030 ($M)
4.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
4.1.5 AbbVie Inc Market 2023-2030 ($M)
4.1.6 Novartis AG Market 2023-2030 ($M)
4.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
4.1.8 Celgene Corporation Market 2023-2030 ($M)
4.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
4.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)
5.Europe Competitive Landscape Market 2023-2030 ($M)
5.1 Market Participation Categorization Market 2023-2030 ($M) - Regional Industry Research
5.1.1 Pfizer Inc Market 2023-2030 ($M)
5.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
5.1.3 Sanofi Market 2023-2030 ($M)
5.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
5.1.5 AbbVie Inc Market 2023-2030 ($M)
5.1.6 Novartis AG Market 2023-2030 ($M)
5.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
5.1.8 Celgene Corporation Market 2023-2030 ($M)
5.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
5.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)
6.APAC Competitive Landscape Market 2023-2030 ($M)
6.1 Market Participation Categorization Market 2023-2030 ($M) - Regional Industry Research
6.1.1 Pfizer Inc Market 2023-2030 ($M)
6.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
6.1.3 Sanofi Market 2023-2030 ($M)
6.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
6.1.5 AbbVie Inc Market 2023-2030 ($M)
6.1.6 Novartis AG Market 2023-2030 ($M)
6.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
6.1.8 Celgene Corporation Market 2023-2030 ($M)
6.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
6.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)
7.MENA Competitive Landscape Market 2023-2030 ($M)
7.1 Market Participation Categorization Market 2023-2030 ($M) - Regional Industry Research
7.1.1 Pfizer Inc Market 2023-2030 ($M)
7.1.2 F. Hoffmann-LA Roche Ltd Market 2023-2030 ($M)
7.1.3 Sanofi Market 2023-2030 ($M)
7.1.4 Bristol-Myers Squibb Company Market 2023-2030 ($M)
7.1.5 AbbVie Inc Market 2023-2030 ($M)
7.1.6 Novartis AG Market 2023-2030 ($M)
7.1.7 GlaxoSmithKline PLC Market 2023-2030 ($M)
7.1.8 Celgene Corporation Market 2023-2030 ($M)
7.1.9 Johnson Johnson Services, Inc Market 2023-2030 ($M)
7.1.10 Takeda Pharmaceutical Company Market 2023-2030 ($M)

LIST OF FIGURES

1.US Hematologic Malignancies Market Revenue, 2023-2030 ($M)
2.Canada Hematologic Malignancies Market Revenue, 2023-2030 ($M)
3.Mexico Hematologic Malignancies Market Revenue, 2023-2030 ($M)
4.Brazil Hematologic Malignancies Market Revenue, 2023-2030 ($M)
5.Argentina Hematologic Malignancies Market Revenue, 2023-2030 ($M)
6.Peru Hematologic Malignancies Market Revenue, 2023-2030 ($M)
7.Colombia Hematologic Malignancies Market Revenue, 2023-2030 ($M)
8.Chile Hematologic Malignancies Market Revenue, 2023-2030 ($M)
9.Rest of South America Hematologic Malignancies Market Revenue, 2023-2030 ($M)
10.UK Hematologic Malignancies Market Revenue, 2023-2030 ($M)
11.Germany Hematologic Malignancies Market Revenue, 2023-2030 ($M)
12.France Hematologic Malignancies Market Revenue, 2023-2030 ($M)
13.Italy Hematologic Malignancies Market Revenue, 2023-2030 ($M)
14.Spain Hematologic Malignancies Market Revenue, 2023-2030 ($M)
15.Rest of Europe Hematologic Malignancies Market Revenue, 2023-2030 ($M)
16.China Hematologic Malignancies Market Revenue, 2023-2030 ($M)
17.India Hematologic Malignancies Market Revenue, 2023-2030 ($M)
18.Japan Hematologic Malignancies Market Revenue, 2023-2030 ($M)
19.South Korea Hematologic Malignancies Market Revenue, 2023-2030 ($M)
20.South Africa Hematologic Malignancies Market Revenue, 2023-2030 ($M)
21.North America Hematologic Malignancies By Application
22.South America Hematologic Malignancies By Application
23.Europe Hematologic Malignancies By Application
24.APAC Hematologic Malignancies By Application
25.MENA Hematologic Malignancies By Application